 A New Way to Discover Innovative Medicine: Approach from the East
Li Chen, Ph.D., Chief Scientific Officer, Roche R&D Center (China) Ltd |
 Aligning Business, Corporate, and International Tax Strategy
Rickey Pate, MBA, JD, Director of Global Tax, Eli Lilly and Company
|
 How to Balance Internal and External Resources to Provide DMPK Support for Drug Discovery in China
Ji Zhang, Ph.D., Director, DMPK, GlaxoSmithKline R&D China
|
 Building an Integrated Biomedical Institute for Innovative Medicine in China
Ling Chen, Ph.D., Director General, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences
|
 Drug Discovery R&D in China: From Functional Capacity Outsourcing to Integrative Partnership
Guoxin Zhu, Ph.D., Director, Discovery Chemistry Research & Technology, Eli Lilly & Company
|
 Accelerate Oncology Clinical Development in Asia
Michael Shi, Ph.D., Director and Biomarker Project Leader, Exploratory Oncology Development, Novartis
|
 The Latest Insights from China into Translational Research for Cancer
Jun Ren, M.D., Ph.D., Clinical Trials Coordination, Peking University School of Oncology/Beijing Cancer Hospital
|
 Strategic Planning for Clinical Development Operations in China: Legal and Regulatory Considerations
Shaoyu Chen, Senior Counsel, Development & Regulatory Law Group, Amgen Inc.
|